Reviews/Dry Eye Disease Treatment/Intense pulsed light improves meibomian gland function
Intense Pulsed Light · DED-IPL-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across twenty primary studies run by independent groups in several countries and using different devices and filters, meibomian gland measures (meibum quality, how easily glands can be expressed, and secretion scores) consistently improved after intense pulsed light in people with meibomian gland dysfunction. One randomized crossover trial [11] showed that adding manual gland squeezing did not change the gland-quality gains, suggesting the light itself is doing the work. A head-to-head randomized trial [4] found the light treatment better than eyelid hygiene for meibum quality and expressibility. The main caveats are that the single placebo-controlled trial [1] measured the tear-film lipid layer rather than grading meibum directly, that many supporting studies have no control group and rely on an examiner's eyeball grading, and that some studies combined the light with gland squeezing so the two effects are hard to separate. The direction of benefit is uniform, but these design limits are why the panel did not place it in the top tier.
Every included study that measured a gland-function endpoint reported improvement after IPL in the same direction [1],[2],[3],[4],[5],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19],[20]. The strongest attribution comes from [11], a randomized crossover in 60 patients where meibomian gland expressibility and meibum quality were not influenced by adding gland expression (p = 0.663 and 0.731 by GEE), isolating IPL's own effect, and from [4], a randomized trial where IPL was superior to eyelid hygiene for meibum quality and expressibility from week 4 (between-group p ≤ 0.021). The only double-masked placebo-controlled trial [1] showed lipid layer grade improving in treated eyes (P < 0.001) but not controls (P = 0.714). Large single-arm series reinforce the signal, with meibum quality improving in 390 eyes [15] (p < 0.001) and meibum grade in 59 eyes [10] (p < 0.001). The contested point: The division is whether the uniform improvement reflects IPL acting on the gland or the ways gland function was measured and co-treated. The single placebo-controlled trial [1] captured lipid-layer output rather than grading meibum directly, and several studies co-administered meibomian gland expression [7],[14],[17],[18],[19], which itself improves expressibility; [11] is the one design that separates the two.
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
A large share of the included corpus co-administers meibomian gland expression with IPL ([7],[14],[17],[18],[19] and combined arms), which mechanically improves expressibility and prevents clean attribution to IPL. Partly rebutted by [11], where MGE/MQ gains were statistically unaffected by adding MGX.
The sole double-masked placebo-controlled RCT [1] measured lipid-layer grade and NIBUT, not meibum expressibility or quality directly, so the strongest controlled evidence for the exact 'gland function' endpoint is one inferential step removed.
Where it remains uncertain. The only placebo-controlled trial [1] measured lipid-layer grade, not meibum directly, and much supporting evidence [12],[15],[20] is uncontrolled with clinician-graded surrogates, often with gland expression co-administered [14],[17],[18],[19].
Aleatory
Response varies by baseline severity and subgroup, e.g. greater gain at higher baseline MGE grade 3 in [3] and persistence differing by parameter in [20].
Epistemic
The only double-masked placebo-controlled trial [1] graded lipid layer and NIBUT, leaving the exact gland-function endpoint without a masked placebo comparison.
Inferential
MQ, MGE and meiboscore are semi-subjective clinician scales [5],[13],[15] standing in for gland function, so the inference to true function depends on scale validity.
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Double-masked placebo-controlled paired-eye RCT confirming improved gland lipid output versus placebo
“Lipid layer grade improved significantly from BL to Day (D) 45 in the treated eye (P < 0.001), but not the control eye (P = 0.714), with 82% of treated eyes improving by at least one LLG.”
Panel auditInternal validity: high · scope of inference: Effect of IPL on tear film lipid quality and symptoms in MGD, not on gland secretory function.Key limitations: no gland function endpoint · small n · tear-film not gland outcomes
RCT (N=50) with active comparator demonstrating IPL superiority for meibum quality and expressibility
“IPL provides faster and more pronounced improvements in meibomian gland function, tear film stability, and patient-reported symptoms over 6 weeks.”
Panel auditInternal validity: medium · scope of inference: Demodex-associated MGD; IPL superior to lid hygiene on gland function over 6 weeks.Key limitations: active (not sham) comparator · Demodex-specific subgroup · short 6-week horizon
RCT across two devices with significant meibum-grade improvement
“SPEED score, NIBUT, lid margin abnormalities, fluorescein staining, FBUT, and meibum grade improved significantly in both groups after IPL compared to before IPL (p < 0.001, respectively).”
Panel auditInternal validity: medium · scope of inference: MGD; meibum grade improves with IPL regardless of device.Key limitations: no non-IPL control · device-comparison design · meiboscore not reported as improved
Prospective measurement of rising meibomian gland yield secretion score across IPL sessions
“TBUT and MGYSS increased consecutively during treatment.”
Panel auditInternal validity: low · scope of inference: Within-patient change in gland secretion after three IPL sessions in MGD.Key limitations: no control arm · significance of MGYSS change not stated · cross-sectional/uncontrolled
4 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direction of effect is unanimous and directly on-endpoint with at least one trial isolating IPL from co-treatment, but reliance on surrogate grades, frequent MGX confounding, and an indirect placebo-controlled endpoint hold confidence at the high end of Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-controlled trial with direct meibum endpoint. The exact gland-function endpoint has no masked placebo comparison; [1] used lipid-layer grade instead. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-masked, placebo-controlled (paired-eye or parallel) RCT with meibum expressibility and quality as pre-specified primary endpoints and no co-administered expression.
Open question: Does IPL improve directly graded meibum expressibility and quality versus placebo when gland expression is withheld? Why it is still open: The only placebo-controlled trial [1] measured lipid-layer output, and trials grading meibum directly [4],[11] have no placebo arm.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19